Description
Product Characteristics:
Participates in signal transduction in hematopoietic cells. Adapter protein that functions as a negative regulator of many signaling pathways that start from receptors at the cell surface. Acts as an E3 ubiquitin-protein ligase, which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and then transfers it to substrates promoting their degradation by the proteasome. Recognizes activated receptor tyrosine kinases, including PDGFA, EGF and CSF1, and terminates signaling.
Subcellular location: Cytoplasm, Cell membrane
Synonyms: C CBL Tyr674, CBL2 Tyr674, CBL2 Y674, p-CBL2 Tyr674, p-CBL2 Y674, C CBL, Cas Br M murine ecotropic retroviral transforming sequence, Cas-Br-M murine ecotropic retroviral transforming sequence, Casitas B lineage lymphoma proto oncogene, Casitas B-lineage lymphoma proto-oncogene, CBL 2, cbl, CBL_HUMAN, CBL2, E3 ubiquitin protein ligase CBL, E3 ubiquitin-protein ligase CBL, Oncogene CBL2, Proto oncogene c CBL, Proto-oncogene c-CBL, RGD1561386, RING finger protein 55, RNF55, Signal transduction protein CBL.
Target Information: This gene is a proto-oncogene that encodes a RING finger E3 ubiquitin ligase. The encoded protein is one of the enzymes required for targeting substrates for degradation by the proteasome. This protein mediates the transfer of ubiquitin from ubiquitin conjugating enzymes (E2) to specific substrates. This protein also contains an N-terminal phosphotyrosine binding domain that allows it to interact with numerous tyrosine-phosphorylated substrates and target them for proteasome degradation. As such it functions as a negative regulator of many signal transduction pathways. This gene has been found to be mutated or translocated in many cancers including acute myeloid leukaemia. Mutations in this gene are also the cause of Noonan syndrome-like disorder. [provided by RefSeq, Mar 2012]